ArticleBMC endocrine disorders2016
Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids - experience from a single centre spanning three decades.
Article in BMC endocrine disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Adrenal lesions in patients with abdominal multitrauma.Endocrine · 2025Article
- [Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Prevalence and Incidence of Fractures in Patients With Nonfunctional Adrenal Tumors.JAMA network open · 2024Article
- Specialty grand challenge in adrenal endocrinology.Frontiers in endocrinology · 2023Article
- High expression of GMNN predicts malignant progression and poor prognosis in ACC.European journal of medical research · 2022Article
- Predictive Factors of Functioning Adrenal Incidentaloma: A 15-Year Retrospective Study.Medicina (Kaunas, Lithuania) · 2022Article
- Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.Frontiers in endocrinology · 2022Article
- The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.Biomedicines · 2021Review
- Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.Frontiers in endocrinology · 2021Article
- Adrenocortical carcinoma: an ominous cause of hirsutism.BMJ case reports · 2019Article
- Severe hyperandrogenism due to ovarian hyperthecosis in a young woman.BMJ case reports · 2019Article
- Presentation, Treatment, Histology, and Outcomes in Adrenal Medullary Hyperplasia Compared With Pheochromocytoma.Journal of the Endocrine Society · 2019Article
- Identification of important invasion and proliferation related genes in adrenocortical carcinoma.Medical oncology (Northwood, London, England) · 2019Article
- Adrenal insufficiency due to bilateral adrenal metastases - A systematic review and meta-analysis.Heliyon · 2019Article
- Clinical characteristics and prognosis of adrenocortical tumors in children.Pediatric surgery international · 2019Article
- Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center.Endocrine · 2018Article
- Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center.Endocrine connections · 2018Article
- Overexpression of HSD17B4 exerts tumor suppressive function in adrenocortical carcinoma and is not associated with hormone excess.Oncotarget · 2017Article
- Clinicopathological features and outcomes of adrenocortical carcinoma: A single institution experience.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
- Importance of Dehydroepiandrosterone Sulfate Assessment with Special Attention for Adrenal Tumours and Arterial Hypertension.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdrenocortical carcinoma (ACC) is a rare malignant disease with a poor prognosis. Our aims were to study survival and to explore prognostic markers.
methodsWe retrospectively investigated the medical records of all 50 ACC patients at a single centre diagnosed between 1985 and 2012 and followed them up until 31/12/2014.
resultsOf this cohort, twenty six (52 %) were females. Adrenalectomy was performed in 48 patients (96 %), and twenty seven (54 %) were treated with adjuvant cytotoxic agents. The tumor sizes ranged from 6 to 20 cm. Overall survival time was 5.5 years (0.3-19.8), the two and five-year survival was 64 and 40 %, respectively. In ENSAT stage II 25/48 patients had a median survival of 7.0 years (0.7-15.5), in stage III 8/48 this was 1.9 (0.4 - 19.8), and in stage IV 15/48 it was 1.2 (0.3-3.6) years. Seventeen patients (34 %) were still alive at the end of 2014. The total follow-up time was 8.4 (0.3-19.8) years. Cell proliferation measured with Ki-67 had a median value of 15 % (2-80) and the urinary steroid profile was clearly pathologic in 29 of 43 (67 %) tested patients. The proliferation index did not significantly predict mortality (Ki-67 ≤ 10 vs. >10 %, 9.0 vs. 3.2 years, P = 0.0833), but resection margins did (R1 vs. R2, P = 0.0066; R0 vs. R2, P < 0.0001). The urinary steroid profile did not predict mortality (normal vs. pathologic urine profile: median survival 6.6 vs. 3.3 years, P = 0.261).
conclusionsThe prognosis was generally poor and macroscopically positive resection margins resulted in a worse prognosis. However, some patients were still alive many years following primary surgery with no sign of residual disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.